… because it requires you to really attach yourself to one topic for four years, and that’s not my personality. I started looking at the Science Park here in Leiden for options. At the time ProQR was looking for five technicians, … that what works. The past year we have been working on optimizing protocols to grow cells from a patient’s skin into …
… long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of … RNA therapies.” But what about gene therapy, isn’t that an option? “There are several reasons to choose RNA therapy over … Can we learn more about our molecules, and does it help to optimize our protocols? Those are just some of the questions …
… with Lilly and Company . The partnership focuses on developing potential medicines using our Axiomer ® RNA … is to progress new medicine technology towards clinical development and, ultimately, to patients via … into diseases of which there are little to no treatment options. In our vision partnerships are true catalyst for the …
… collaboration with Lilly. The partnership focuses on developing potential medicines using our Axiomer RNA editing … beginning, ProQR has been focused on RNA technologies to develop medicines for people and families with high unmet … additional targets, along with an option for Lilly to opt in for more. Lilly is a leader in RNA therapeutics, and …
… and Cambridge, Massachusetts, USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet … activities include: Prepare mechanistic minimal PBPK and/ (population) PKPD M&S-based strategies to support discovery … generate predictive (human) exposure profiles and to guide optimal dosing strategies and ensure therapeutic efficacy and …
… approaches to drive scientific and operational excellence. Develop and determine optimal methods for new assignments by … we are true believers of the value of a workforce in which people from diverse backgrounds are encouraged to develop … and professionally. We believe that happy and energized people, working well together in an environment in which they …
… Klein, who was at the forefront of the Axiomer® technology development. ProQR’s Sr. Vice President Innovation makes his point about the promise of Axiomer® technology: “This opens up a whole new way of designing medicines for genetic … variety of diseases with currently no or limited treatment options. A new approach The Axiomer® technology builds on …
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
